Korro Bio said preclinical data on KRRO-121 suggest its GalNAc-conjugated RNA editing oligonucleotide could control ammonia in urea cycle disorders across mutat

Korro Bio said preclinical data on KRRO-121 suggest its GalNAc-conjugated RNA editing oligonucleotide could control ammonia in urea cycle disorders across mutational backgrounds. The company will present the findings at SSIEM 2026, underscoring its rare-disease pipeline push.